LAVA Therapeutics NV is an immuno-oncology company, which engages in the proprietary Gammabody platform to develop a portfolio of bispecific gamma delta T cell engagers for the potential treatment of solid tumors and hematological malignancies. The company was founded by Erik van den Berg in 2016 and is headquartered in Utrecht, the Netherlands.
Sector:
Health Technology
Industry:
Biotechnology
Employees:
34
Frequently Asked Questions
Market cap, also known as market capitalization, is the total market value of a company. It's calculated by multiplying the current market price by the total number of shares outstanding. LAVA Therapeutics NV market cap is $45.77M.
52 week high is the highest price of a stock in the past 52 weeks, or one year. LAVA Therapeutics NV 52 week high is $2.00 as of November 22, 2026.
52 week low is the lowest price of a stock in the past 52 weeks, or one year. LAVA Therapeutics NV 52 week low is $0.8502 as of November 22, 2026.
LAVA Therapeutics NV stock price today is $1.74.
LAVA Therapeutics NV stock price yesterday was $1.81.
The Price-to-Earnings (or P/E) ratio is a commonly used tool for valuing a company. It's calculated by dividing the current share price by the earnings per share (or EPS). It can also be calculated by dividing the company's Market Cap by the Net Profit. LAVA Therapeutics NV's P/E ratio is -2.02.
The Price-to-Book (P/B) ratio is a commonly used tool for valuing a company. It's calculated by dividing a company's market capitalization by its book value. LAVA Therapeutics NV P/B ratio is 3.6086.
The 50-day moving average is a frequently used data point by active investors and traders to understand the trend of a stock. It's calculated by averaging the closing stock price over the previous 50 trading days. LAVA Therapeutics NV 50-day moving average is $1.61.